Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
I. Henrı́quez, Mack Roach, Todd M. Morgan, Alberto Bossi, Junior Gómez, Oscar Abuchaibe, Felipe Couñago
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation. However, due to the rapidly changing therapeutic landscape in mCRPC, it is difficult for clinicians to keep up to date with the latest innovations in this area. In the present narrative review, we discuss the current and emerging therapies for mCRPC as well as the clinical and molecular factors that can help predict which patients are most likely to benefit from these novel agents.